Cite as: S. Bangaru *et al.*, *Science* 10.1126/science.abe1502 (2020).

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

Sandhya Bangaru¹, Gabriel Ozorowski¹, Hannah L. Turner¹, Aleksandar Antanasijevic¹, Deli Huang², Xiaoning Wang³, Jonathan L. Torres¹, Jolene K. Diedrich³, Jing-Hui Tian⁴, Alyse D. Portnoff⁴, Nita Patel⁴, Michael J. Massare⁴, John R. Yates III³, David Nemazee², James C. Paulson^{2,3}, Greg Glenn⁴, Gale Smith⁴, Andrew B. Ward^{1*}

¹Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. ²Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA. ³Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA. ⁴Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.

*Corresponding author. Email: andrew@scripps.edu

Vaccine efforts against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the current COVID-19 pandemic are focused on SARS-CoV-2 spike glycoprotein, the primary target for neutralizing antibodies. We performed cryo-EM and site-specific glycan analysis of one of the leading subunit vaccine candidates from Novavax based on a full-length spike protein formulated in polysorbate 80 (PS 80) detergent. Our studies reveal a stable prefusion conformation of the spike immunogen with slight differences in the S1 subunit compared to published spike ectodomain structures. We also observed novel interactions between the spike trimers allowing formation of higher order spike complexes. This study confirms the structural integrity of the full-length spike protein immunogen and provides a basis for interpreting immune responses to this multivalent nanoparticle immunogen.

Severe acute respiratory syndrome coronavirus (SARS-CoV) caused a global outbreak from 2002-2003 (1). SARS-CoV-2, from the same lineage of the β -CoV genus as SARS-CoV, recently emerged in China, spreading rapidly and infecting more than 28 million people worldwide by September 2020 (2). The coronavirus disease (COVID-19) caused by SARS-CoV-2 was declared a pandemic by the World Health Organization (WHO). In response, several SARS-CoV-2 vaccine candidates are being developed and tested at various stages of clinical trials (3–5). The SARS-CoV-2 spike (S) trimeric glycoprotein is a focus of vaccine development because it is the primary target of host immune defenses (5, 6).

Like other type 1 fusion proteins, the SARS-CoV-2 S prefusion trimer is metastable and undergoes structural rearrangement from a prefusion to a post fusion conformation upon S-protein receptor binding and cleavage (7, 8). The structure of the stabilized SARS-CoV-2 spike ectodomain has been solved in its prefusion conformation and resembles the SARS-CoV spike (9–11). Here, we describe the structure of a leading SARS-CoV-2 S vaccine candidate (NVAX-CoV2373) based on a full-length S, residues 1-1273 which includes the transmembrane (TM) and the cytoplasmic tail (CT) (Fig. 1A). The final construct, SARS-CoV-2-3Q-2P, was also modified at the S1/S2 polybasic cleavage site from RRAR to QQAQ to render it protease resistant along with 2 proline substitutions at residues K986 and V987 in the S2 fusion machinery core for enhanced stability (Fig. 1A). The FL spikes, expressed and

purified from insect cells, were formulated in 0.01% (v/v) polysorbate 80 (PS 80) detergent. To characterize the structural integrity of the 3Q-2P-FL immunogen, we performed negative stain electron microscopy (nsEM) of the FL spike constituted in PS 80 in the presence of Matrix-M adjuvant, recapitulating the vaccine formulation being tested in humans. Imaging revealed trimeric spike proteins present as free trimers or as multi-trimer rosettes, containing as many as 14 trimers with their transmembrane domains enclosed in micellar cores of PS 80 detergent (Fig. 1B). Tight clustering of the spikes in the NVAX-CoV2373 nanoparticle formulation may lead to stronger immune responses over soluble trimers alone, similar to other viral glycoprotein immunogens (HA and RSV F) (12, 13).

We next performed single particle cryo-EM on the spike formulated in PS 80 detergent (Fig. 2A). Initial 2D classification revealed the presence of 2 distinct classes: free spike trimers and dimers of trimers (Fig. 2A). The three-fold symmetric (C3) reconstruction of the free spike trimer resulted in 3.6 Å resolution map while the asymmetric reconstruction (C1) refined to 3.8 Å resolution (Fig. 2B and fig. S1, A and B). In previous structures, RBDs exist in either a closed (RBD-down) or an open (RBD-up) conformation that can engage in ACE2 binding (9, 10, 14). In contrast, we observed all three RBDs on the 3Q-2P-FL spike trimer were in the closed conformation in our reconstructions (Fig. 2B and fig. S1C). Despite the RBD-down conformation, binding analysis of the

3Q-2P-FL immunogen to ACE2 by both bio-layer interferometry and ELISA clearly show binding to ACE2, indicating that the RBD is dynamic and the receptor binding site accessible (15). Another study on the prefusion structure of a full-length spike protein reported similar findings with RBDs clamped down as a consequence of potential clashes between S2 residues 828-853 and SD1 when RBD is in open conformation (16). Recent reports by Henderson *et al.* have revealed that introducing mutations and removing N-linked glycosylation at certain positions can alter the propensity toward 'up' and 'down' states of the RBD (17, 18).

Overall, our cryo-EM map was well resolved in both S1 and S2 subunits (fig. S1D), enabling us to model the full S1 NTD and CTD domains that were less resolved in previous structures (9, 10). Our final atomic model contains residues 14-1146 with breaks only in the flexible loop (619-631) and the cleavage site (678-688) (Fig. 2C). Superimposition of the coordinate models of 3Q-2P-FL spike with published spike structures (PDB Id: 6VXX and 6VSB) revealed substantial domain rearrangements in the S1 subunit of 3Q-2P-FL spike (Fig. 2D). The S1 NTD rotated $\sim 14^\circ$ relative to published models while the CTD and subdomains showed minor local rearrangements (Fig. 2D). Another recent study also observed differences in NTD conformations at lower pH, although our cryo-EM studies were carried out at neutral pH (19). In our 3Q-2P-FL structure we observed a shift in residues flanking the 615-635 loop, resulting in a salt-bridge between residue Asp 614 on one protomer and Lys 854 on a neighboring protomer (Fig. 3A). This observation is particularly interesting given the increased prevalence of D614G mutation in the emerging SARS-CoV-2 strains and its potential role in viral transmission and pathogenesis (20). The 615-635 loop that is generally disordered in spike trimer structures including our was recently modeled as a helix (PDB Id: 6X6P) (Fig. 3B), although the cryo-EM density (EMD-22078) does not support this assignment (fig. S1E) (17).

We observed 2 additional densities in the S1 subunit that did not correspond to peptide or glycans within the spike (fig. S2A). The first density was buried within a hydrophobic pocket of the CTD (Fig. 3C). We have previously showed palmitoleic acid occupying a similar pocket in the structure of porcine epidemic diarrhea virus (PEDV) (21). This density in SARS-CoV-2 S corresponded to linoleic acid, a polyunsaturated fatty acid; the presence of this ligand was confirmed by mass spectrometry of 3Q-2P-FL spike (fig. S2, B and C). The main chain carboxyl group of linoleic acid interacts with the R408 and Q409 residues of the RBD from the adjacent protomer, potentially stabilizing the observed RBD-down state (Fig. 3C) and consistent with a recent report (22). The second unassigned density, present in the NTD, was larger and more surface exposed than the first (Fig. 3D and fig. S2D). The aliphatic tail of PS 80 fit well into this hydrophobic pocket while

the carbonyl and hydroxyl groups were in proximity to residues R190 and H207 with potential for multiple hydrogen bonds between them (Fig. 3D and fig. S2D). The location of the PS80 ligand provides a possible explanation for the S1 shift seen in our FL trimer density. While PS80 is unique to the formulation of the Novavax 3Q-2P-FL immunogen other ligands may also bind this pocket and provide a potential target for drug design against SARS-CoV-2.

Classification of multimeric spike trimer particles yielded two separate classes; a dimer-of-trimers class that reconstructed to a final resolution of 4.5 Å with 2-fold symmetry and a trimer-of-trimers class that was resolved to 8.0 Å resolution (Fig. 4, A and B, and fig. S3A). In both reconstructions, the interaction between each pair of trimers involved the SD2 of one protomer from each trimer engaging with the NTD of the adjacent trimer (Fig. 4C), with trimer axes tilted 44.5 degrees relative to each other. The dimer-of-trimer interaction was mainly coordinated by the 615-635 loop which, in contrast to the free trimer structure, was now fully resolved (Fig. 4D). The loop reaches into and induces subtle changes to a pocket on the adjacent NTD compared to the free trimer model (Fig. 4D). Residues Y145 and H146 in the binding pocket appear to switch positions in the loop-bound state resulting in a salt bridge interaction between H146 and D627 and potential stacking between W152 and H146 (Fig. 4E). We also observed minor displacement of residues 68-75 and 248-250 surrounding the pocket. In the dimer-of-trimers we also observed N282 glycans at the dimer interface (fig. S3B). As a control we also performed cryo-EM studies of the SARS-CoV-2-3Q-FL (without 2P). Notably, the structures of the trimers were identical, and we also observed dimers-of-trimers (fig. S3, C to E)

Sequence alignment of residues in the 615-635 loop and corresponding NTD binding pocket across representative CoV strains belonging to lineage B of betacoronaviruses revealed residues 621-PVAIHADQ-628 are well conserved, but there are notable differences in the binding pocket residues (fig. S4A). Significant gaps in the interacting NTD loops along with the absence of H146 at the corresponding site on SARS-CoV make it unlikely that SARS-CoV participates in similar inter-trimeric interactions. While the residues in the NTD pocket were almost identical between SARS-CoV-2 and its closely related bat strain Bat-SL-RatG13, we observed some residue differences and 1-3 amino acid deletions in the loops comprising the NTD binding pocket of representative strains Bat-SL-CoVZC45, BetaCoV/pangolin/Guandong/1/2019 and BetaCoV/pangolin/Guangxi/P4L/2007 (fig. S4A).

Some human CoVs (HCoV), including OC43, exclusively use NTD-sialic acid interactions as their receptor engagement while others like Middle East Respiratory Syndrome (MERS) CoV that use the CTD-RBD for primary receptor binding have also been reported to bind sialic acid (SA) receptors via their

NTD to aid initial attachment to the host cells (23–25). Structural comparisons of the SARS-CoV-2 NTD dimerization pocket with that of the SA binding site on MERS spike revealed that they did not coincide with each other (PDB ID: 6Q04) (25) (fig. S4B). Computational and structural studies have proposed residues on SARS-CoV-2 spike that may be involved in SA binding (26, 27). Interestingly, structural comparison of this putative glycan binding site to the dimerization site revealed them situated adjacent to one another with residues in loop 70 contributing to both the binding pockets (fig. S4C).

We next performed cell surface expression and pseudovirus replication assays with SARS-CoV-2 wild-type (WT) spike and spikes containing mutations in the 615–635 loop and NTD pocket. Each residue in the loop 621-PVAIHADQ-628 and residue H146 in the binding pocket were individually mutated to either alanine or glycine. Additionally, we made a spike construct with all eight residues 621-PVAIHADQ-628 replaced with a glycine-serine (GS) linker to completely abrogate binding. Compared to the WT, the mutants generally exhibited lower levels of infectivity (Fig. 4F). Cell surface expression of these mutants in 293T cells revealed that these mutations also disrupted surface expression of the spike protein, with linear correlation between surface expression and pseudovirus replication (Fig. 4G).

Glycans on viral glycoproteins play a wide role in protein folding, stability, immune recognition and also in facilitating immune evasion. We therefore conducted site-specific glycosylation analysis of the SARS-CoV-2 prefusion spike protein produced in SF9 insect cells as previously described (28) to assess the extent of glycosylation and the degree of glycan processing from high mannose/hybrid type to complex type. The analysis detected glycosylation at all 22 N-linked glycan sequons present on SARS-CoV-2 spike (Fig. 4H). Overall there was high glycan occupancy of over >98%, with only two sites, 603 and 657, more than 5% unoccupied. Interestingly, we did not see clear glycan density at either 603 or 657 in the cryo-EM reconstruction of the 3Q-2P-FL spike. Most sites showed extensive glycan processing to complex/paucimannose type glycans, with only four sites exhibiting ≥40% oligomannose. The glycan analysis also confirmed the presence of glycans at sites I158, I173 and I194 present in the membrane proximal region of the spike not resolved by cryo-EM. By comparison with site specific glycan processing of the spike protein produced in mammalian HEK293F cells, both mammalian cells and insect cells exhibit extensive processing at most sites. In general however processing of glycans on the 2019 CoV prefusion spike protein from insect cells was somewhat greater, particularly at sites 709 and 717 which were predominately oligomannose in spike from HEK293 cells but exclusively complex/paucimannose in spike from Sf9 cells (29).

Our structural work is consistent with the burgeoning

body of spike structures, albeit with important differences in the rearrangement of S1 domains and formation of inter-trimer interactions (9, 10). Both these findings were seen in the full-length spike immunogens assembled into compact and dense nanoparticles. Cryo-electron tomographic reconstructions of intact SARS-CoV-2 virions showed a relatively dispersed distribution of spike protein trimers on the viral surface and no evidence of higher order aggregates (30). However, another study showed that the D614G mutation present in close proximity to the dimerization loop results in a several fold increase of spike numbers on the viral surface, resulting in higher spike protein density and a more infectious virion (20). The greater density may be aided by the ability to form such higher order multimers. Alternatively, the loop that mediates inter-spike interactions may play a role in viral viability, consistent with our loop mutant data.

Analysis of safety and immunogenicity of the Novavax SARS-CoV-2-3Q-2P-FL immunogen in mice and baboons revealed strong B- and T-cell responses to the vaccine with no evidence of vaccine-associated enhanced respiratory disease (VAERD) (15). Phase 1/2 clinical trial results showed that the vaccine induced immune responses exceeding levels seen in COVID-19 patients (31). Overall, we found that NVAX-CoV2372 is stable, homogeneous, and locked in the antigenically preferred prefusion conformation. With structural, biophysical, and antigenic characterization now complete, ongoing evaluation in humans will provide the true proof-of-principle for this vaccine concept.

REFERENCES AND NOTES

1. J. D. Cherry, P. Krogstad, SARS: The first pandemic of the 21st century. *Pediatr. Res.* **56**, 1–5 (2004). [doi:10.1203/01.PDR.0000129184.87042.FC](https://doi.org/10.1203/01.PDR.0000129184.87042.FC) [Medline](#)
2. N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F. Zhan, X. Ma, D. Wang, W. Xu, G. Wu, G. F. Gao, W. Tan, China Novel Coronavirus Investigating and Research Team, A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl. J. Med.* **382**, 727–733 (2020). [doi:10.1056/NEJMoa2001017](https://doi.org/10.1056/NEJMoa2001017) [Medline](#)
3. F. Amanat, F. Krammer, SARS-CoV-2 vaccines: Status report. *Immunity* **52**, 583–589 (2020). [doi:10.1016/j.immuni.2020.03.007](https://doi.org/10.1016/j.immuni.2020.03.007) [Medline](#)
4. N. Lurie, M. Saville, R. Hatchett, J. Halton, Developing Covid-19 vaccines at pandemic speed. *N. Engl. J. Med.* **382**, 1969–1973 (2020). [doi:10.1056/NEJMp2005630](https://doi.org/10.1056/NEJMp2005630) [Medline](#)
5. G. Salvatori, L. Luberto, M. Maffei, L. Aurisicchio, G. Roscilli, F. Palombo, E. Marra, SARS-CoV-2 spike protein: An optimal immunological target for vaccines. *J. Transl. Med.* **18**, 222 (2020). [doi:10.1186/s12967-020-02392-y](https://doi.org/10.1186/s12967-020-02392-y) [Medline](#)
6. S. Belouzard, J. K. Millet, B. N. Licitra, G. R. Whittaker, Mechanisms of coronavirus cell entry mediated by the viral spike protein. *Viruses* **4**, 1011–1033 (2012). [doi:10.3390/v4061011](https://doi.org/10.3390/v4061011) [Medline](#)
7. A. C. Walls, M. A. Tortorici, J. Snijder, X. Xiong, B.-J. Bosch, F. A. Rey, D. Veasler, Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. *Proc. Natl. Acad. Sci. U.S.A.* **114**, 11157–11162 (2017). [doi:10.1073/pnas.1708727114](https://doi.org/10.1073/pnas.1708727114) [Medline](#)
8. B. J. Bosch, R. van der Zee, C. A. de Haan, P. J. Rottier, The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex. *J. Virol.* **77**, 8801–8811 (2003). [doi:10.1128/JVI.77.16.8801-8811.2003](https://doi.org/10.1128/JVI.77.16.8801-8811.2003) [Medline](#)
9. A. C. Walls, Y.-J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, D. Veasler, Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* **181**, 281–292.e6 (2020). [doi:10.1016/j.cell.2020.02.058](https://doi.org/10.1016/j.cell.2020.02.058) [Medline](#)

10. D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C.-L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**, 1260–1263 (2020). [doi:10.1126/science.abb2507](https://doi.org/10.1126/science.abb2507) [Medline](#)
11. N. G. Herrera, N. C. Morano, A. Celikgil, G. I. Georgiev, R. J. Malonis, J. H. Lee, K. Tong, O. Vergnolle, A. B. Massimi, L. Y. Yen, A. J. Noble, M. Kopylov, J. B. Bonanno, S. C. Garrett-Thomson, D. B. Hayes, R. H. Bortz, A. S. Wirchnianski, C. Florez, E. Laudermitch, D. Haslwanter, J. M. Fels, M. E. Dieterle, R. K. Jangra, J. Barnhill, A. Mengotto, D. Kimmel, J. P. Daily, L. A. Pirofski, K. Chandran, M. Brenowitz, S. J. Garforth, E. T. Eng, J. R. Lai, S. C. Almo, Characterization of the SARS-CoV-2 S protein: Biophysical, biochemical, structural, and antigenic analysis. *bioRxiv* 2020.06.14.150607 [Preprint], 17 June 2020; <https://doi.org/10.1101/2020.06.14.150607>
12. G. Smith, R. Raghunandan, Y. Wu, Y. Liu, M. Massare, M. Nathan, B. Zhou, H. Lu, S. Boddapati, J. Li, D. Flyer, G. Glenn, Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. *PLOS ONE* **7**, e50852 (2012). [doi:10.1371/journal.pone.0050852](https://doi.org/10.1371/journal.pone.0050852) [Medline](#)
13. V. Shinde, L. Fries, Y. Wu, S. Agrawal, I. Cho, D. N. Thomas, M. Spindler, E. Lindner, T. Hahn, J. Plested, D. Flyer, M. J. Massare, B. Zhou, A. Fix, G. Smith, G. M. Glenn, Improved titers against influenza drift variants with a nanoparticle vaccine. *N. Engl. J. Med.* **378**, 2346–2348 (2018). [doi:10.1056/NEJMc1803554](https://doi.org/10.1056/NEJMc1803554) [Medline](#)
14. J. Shang, G. Ye, K. Shi, Y. Wan, C. Luo, H. Aihara, Q. Geng, A. Auerbach, F. Li, Structural basis of receptor recognition by SARS-CoV-2. *Nature* **581**, 221–224 (2020). [doi:10.1038/s41586-020-2179-y](https://doi.org/10.1038/s41586-020-2179-y) [Medline](#)
15. J.-H. Tian, N. Patel, R. Haupt, H. Zhou, S. Weston, H. Hammond, J. Lague, A. D. Portnoff, J. Norton, M. Guebre-Xabier, B. Zhou, K. Jacobson, S. Maciejewski, R. Khatoon, M. Wisniewska, W. Moffitt, S. Kluepfel-Stahl, B. Ekechukwu, J. Papin, S. Boddapati, C. J. Wong, P. A. Piedra, M. B. Frieman, M. J. Massare, L. Fries, K. L. Bengtsson, L. Stertman, L. Ellingsworth, G. Glenn, G. Smith, SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice. *bioRxiv* 2020.06.29.178509 [Preprint], 30 June 2020; <https://doi.org/10.1101/2020.06.29.178509>
16. Y. Cai, J. Zhang, T. Xiao, H. Peng, S. M. Sterling, R. M. Walsh Jr., S. Rawson, S. Rits-Volloch, B. Chen, Distinct conformational states of SARS-CoV-2 spike protein. *Science* **369**, 1586–1592 (2020). [doi:10.1126/science.abd4251](https://doi.org/10.1126/science.abd4251) [Medline](#)
17. R. Henderson, R. J. Edwards, K. Mansouri, K. Janowska, V. Stalls, M. Kopp, B. F. Haynes, P. Acharya, Glycans on the SARS-CoV-2 spike control the receptor binding domain conformation. *bioRxiv* 2020.06.26.173765 [Preprint], 26 June 2020; <https://doi.org/10.1101/2020.06.26.173765>
18. R. Henderson, R. J. Edwards, K. Mansouri, K. Janowska, V. Stalls, S. M. C. Gobeil, M. Kopp, D. Li, R. Parks, A. L. Hsu, M. J. Borgnia, B. F. Haynes, P. Acharya, Controlling the SARS-CoV-2 spike glycoprotein conformation. *Nat. Struct. Mol. Biol.* **27**, 925–933 (2020). [doi:10.1038/s41594-020-0479-4](https://doi.org/10.1038/s41594-020-0479-4) [Medline](#)
19. T. Zhou, Y. Tsymbovsky, A. S. Olia, J. Gorman, M. A. Rapp, G. Cerutti, P. S. Katsamba, A. Nazzari, A. Schon, P. D. Wang, J. Bimela, W. Shi, I. T. Teng, B. Zhang, J. C. Boyington, G. Y. Chuang, J. M. Sampson, M. Sastry, T. Stephens, J. Stuckey, S. Wang, R. A. Friesner, D. D. Ho, J. R. Mascola, L. Shapiro, P. D. Kwong, A pH-dependent switch mediates conformational masking of SARS-CoV-2 spike. *bioRxiv* 2020.07.04.187989 [Preprint], 4 July 2020; <https://doi.org/10.1101/2020.07.04.187989>
20. L. Zhang, C. B. Jackson, H. Mou, A. Ojha, E. S. Rangarajan, T. Izard, M. Farzan, H. Choe, The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. *bioRxiv* 2020.06.12.148726 [Preprint], 12 June 2020; <https://doi.org/10.1101/2020.06.12.148726>
21. R. N. Kirchdoerfer, M. Bhandari, O. Martini, L. M. Sewall, S. Bangaru, K.-J. Yoon, A. B. Ward, Structure and immune recognition of the porcine epidemic diarrhea virus spike protein. *bioRxiv* 2020.02.18.955195 [Preprint], 19 February 2020; <https://doi.org/10.1101/2020.02.18.955195>
22. C. Toelzer, K. Gupta, S. K. N. Yadav, U. Borucu, A. D. Davidson, M. Kavanagh Williamson, D. K. Shoemark, F. Garzoni, O. Stauffer, R. Milligan, J. Capin, A. J. Mulholland, J. Spatz, D. Fitzgerald, I. Berger, C. Schaffitzel, Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. *Science* eabd3255 (2020). [doi:10.1126/science.abd3255](https://doi.org/10.1126/science.abd3255) [Medline](#)
23. R. J. G. Hulsmit, Y. Lang, M. J. G. Bakkers, W. Li, Z. Li, A. Schouten, B. Ophorst, F. J. M. van Kuppeveld, G.-J. Boons, B.-J. Bosch, E. G. Huizinga, R. J. de Groot, Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 2681–2690 (2019). [doi:10.1073/pnas.1809667116](https://doi.org/10.1073/pnas.1809667116) [Medline](#)
24. W. Li, R. J. G. Hulsmit, I. Widjaja, V. S. Raj, R. McBride, W. Peng, W. Widagdo, M. A. Tortorici, B. van Dieren, Y. Lang, J. W. M. van Lent, J. C. Paulson, C. A. M. de Haan, R. J. de Groot, F. J. M. van Kuppeveld, B. L. Haagmans, B.-J. Bosch, Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. *Proc. Natl. Acad. Sci. U.S.A.* **114**, E8508–E8517 (2017). [doi:10.1073/pnas.1712592114](https://doi.org/10.1073/pnas.1712592114) [Medline](#)
25. Y. J. Park, A. C. Walls, Z. Wang, M. M. Sauer, W. Li, M. A. Tortorici, B.-J. Bosch, F. DiMaio, D. Veelsler, Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors. *Nat. Struct. Mol. Biol.* **26**, 1151–1157 (2019). [doi:10.1038/s41594-019-0334-7](https://doi.org/10.1038/s41594-019-0334-7) [Medline](#)
26. E. Milanetti, M. Miotto, L. Di Rienzo, M. Monti, G. Gosti, G. Ruocco, In-silico evidence for two receptors based strategy of SARS-CoV-2. *bioRxiv* 2020.03.24.006197 [Preprint], 6 April 2020; <https://doi.org/10.1101/2020.03.24.006197>
27. M. Awasthi, S. Gulati, D. P. Sarkar, S. Tiwari, S. Kateriya, P. Ranjan, S. K. Verma, N-terminal domain (NTD) of SARS-CoV-2 spike-protein structurally resembles MERS-CoV NTD sialoside-binding pocket. *Research Square* rs.3.rs.37300/v1 [Preprint], 22 June 2020; <https://doi.org/10.21203/rs.3.rs-37300/v1>
28. L. Cao, M. Pauthner, R. Andrabi, K. Rantalainen, Z. Berndsen, J. K. Diedrich, S. Menis, D. Sok, R. Bastidas, S. R. Park, C. M. Delahunty, L. He, J. Guenaga, R. T. Wyatt, W. R. Schief, A. B. Ward, J. R. Yates III, D. R. Burton, J. C. Paulson, Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer. *Nat. Commun.* **9**, 3693 (2018). [doi:10.1038/s41467-018-06121-4](https://doi.org/10.1038/s41467-018-06121-4) [Medline](#)
29. Y. Watanabe, J. D. Allen, D. Wrapp, J. S. McLellan, M. Crispin, Site-specific glycan analysis of the SARS-CoV-2 spike. *Science* **369**, 330–333 (2020). [doi:10.1126/science.abb9983](https://doi.org/10.1126/science.abb9983) [Medline](#)
30. Z. Ke, J. Oton, K. Qu, M. Cortese, V. Zila, L. McKeane, T. Nakane, J. Zivanov, C. J. Neufeldt, B. Cerikan, J. M. Lu, J. Peukes, X. Xiong, H.-G. Kräusslich, S. H. W. Scheres, R. Bartenschlager, J. A. G. Briggs, Structures and distributions of SARS-CoV-2 spike proteins on intact virions. *Nature* 10.1038/s41586-020-2665-2 (2020). [doi:10.1038/s41586-020-2665-2](https://doi.org/10.1038/s41586-020-2665-2) [Medline](#)
31. C. Keech, G. Albert, I. Cho, A. Robertson, P. Reed, S. Neal, J. S. Plested, M. Zhu, S. Cloney-Clark, H. Zhou, G. Smith, N. Patel, M. B. Frieman, R. E. Haupt, J. Logue, M. McGrath, S. Weston, P. A. Piedra, C. Desai, K. Callahan, M. Lewis, P. Price-Abbott, N. Formica, V. Shinde, L. Fries, J. D. Lickliter, P. Griffin, B. Wilkinson, G. M. Glenn, Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. *N. Engl. J. Med.* 10.1056/NEJMoa2026920 (2020). [doi:10.1056/NEJMoa2026920](https://doi.org/10.1056/NEJMoa2026920) [Medline](#)
32. C. S. Potter, H. Chu, B. Frey, C. Green, N. Kisseberth, T. J. Madden, K. L. Miller, K. Nahrstedt, J. Pulokas, A. Reilein, D. Tchong, D. Weber, B. Carragher, Legion: A system for fully automated acquisition of 1000 electron micrographs a day. *Ultramicroscopy* **77**, 153–161 (1999). [doi:10.1016/S0304-3991\(99\)00043-1](https://doi.org/10.1016/S0304-3991(99)00043-1) [Medline](#)
33. G. C. Lander, S. M. Stagg, N. R. Voss, A. Cheng, D. Fellmann, J. Pulokas, C. Yoshioka, C. Irving, A. Mulder, P.-W. Lau, D. Lyumkis, C. S. Potter, B. Carragher, Appion: An integrated, database-driven pipeline to facilitate EM image processing. *J. Struct. Biol.* **166**, 95–102 (2009). [doi:10.1016/j.jsb.2009.01.002](https://doi.org/10.1016/j.jsb.2009.01.002) [Medline](#)
34. N. R. Voss, C. K. Yoshioka, M. Radermacher, C. S. Potter, B. Carragher, DoG Picker and TiltPicker: Software tools to facilitate particle selection in single particle electron microscopy. *J. Struct. Biol.* **166**, 205–213 (2009). [doi:10.1016/j.jsb.2009.01.004](https://doi.org/10.1016/j.jsb.2009.01.004) [Medline](#)
35. T. Ogura, K. Iwasaki, C. Sato, Topology representing network enables highly accurate classification of protein images taken by cryo electron-microscope without masking. *J. Struct. Biol.* **143**, 185–200 (2003). [doi:10.1016/j.jsb.2003.08.005](https://doi.org/10.1016/j.jsb.2003.08.005) [Medline](#)
36. C. Suloway, J. Pulokas, D. Fellmann, A. Cheng, F. Guerra, J. Quispe, S. Stagg, C. S. Potter, B. Carragher, Automated molecular microscopy: The new Legion system. *J. Struct. Biol.* **151**, 41–60 (2005). [doi:10.1016/j.jsb.2005.03.010](https://doi.org/10.1016/j.jsb.2005.03.010) [Medline](#)
37. S. Q. Zheng, E. Palovcak, J.-P. Armache, K. A. Verba, Y. Cheng, D. A. Agard, MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-

- electron microscopy. *Nat. Methods* **14**, 331–332 (2017). [doi:10.1038/nmeth.4193](https://doi.org/10.1038/nmeth.4193) [Medline](#)
38. A. Punjani, J. L. Rubinstein, D. J. Fleet, M. A. Brubaker, cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. *Nat. Methods* **14**, 290–296 (2017). [doi:10.1038/nmeth.4169](https://doi.org/10.1038/nmeth.4169) [Medline](#)
 39. K. Zhang, Gctf: Real-time CTF determination and correction. *J. Struct. Biol.* **193**, 1–12 (2016). [doi:10.1016/j.jsb.2015.11.003](https://doi.org/10.1016/j.jsb.2015.11.003) [Medline](#)
 40. J. Zivanov, T. Nakane, B. O. Forsberg, D. Kimanius, W. J. H. Hagen, E. Lindahl, S. H. W. Scheres, New tools for automated high-resolution cryo-EM structure determination in RELION-3. *eLife* **7**, e42166 (2018). [doi:10.7554/eLife.42166](https://doi.org/10.7554/eLife.42166) [Medline](#)
 41. P. Emsley, M. Crispin, Structural analysis of glycoproteins: Building N-linked glycans with Coot. *Acta Crystallogr. D Struct. Biol.* **74**, 256–263 (2018). [doi:10.1107/S2059798318005119](https://doi.org/10.1107/S2059798318005119) [Medline](#)
 42. R. Y. Wang, Y. Song, B. A. Barad, Y. Cheng, J. S. Fraser, F. DiMaio, Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta. *eLife* **5**, e17219 (2016). [doi:10.7554/eLife.17219](https://doi.org/10.7554/eLife.17219) [Medline](#)
 43. B. A. Barad, N. Echols, R. Y.-R. Wang, Y. Cheng, F. DiMaio, P. D. Adams, J. S. Fraser, EMRinger: Side chain-directed model and map validation for 3D cryo-electron microscopy. *Nat. Methods* **12**, 943–946 (2015). [doi:10.1038/nmeth.3541](https://doi.org/10.1038/nmeth.3541) [Medline](#)
 44. C. J. Williams, J. J. Headd, N. W. Moriarty, M. G. Prisant, L. L. Videau, L. N. Deis, V. Verma, D. A. Keedy, B. J. Hintze, V. B. Chen, S. Jain, S. M. Lewis, W. B. Arendall III, J. Snoeyink, P. D. Adams, S. C. Lovell, J. S. Richardson, D. C. Richardson, MolProbity: More and better reference data for improved all-atom structure validation. *Protein Sci.* **27**, 293–315 (2018). [doi:10.1002/pro.3330](https://doi.org/10.1002/pro.3330) [Medline](#)
 45. N. W. Moriarty, R. W. Grosse-Kunstleve, P. D. Adams, electronic Ligand Builder and Optimization Workbench (eLBOW): A tool for ligand coordinate and restraint generation. *Acta Crystallogr. D Biol. Crystallogr.* **65**, 1074–1080 (2009). [doi:10.1107/S0907444909029436](https://doi.org/10.1107/S0907444909029436) [Medline](#)
 46. T. D. Goddard, C. C. Huang, E. C. Meng, E. F. Pettersen, G. S. Couch, J. H. Morris, T. E. Ferrin, UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Sci.* **27**, 14–25 (2018). [doi:10.1002/pro.3235](https://doi.org/10.1002/pro.3235) [Medline](#)
 47. E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, T. E. Ferrin, UCSF Chimera—A visualization system for exploratory research and analysis. *J. Comput. Chem.* **25**, 1605–1612 (2004). [doi:10.1002/jcc.20084](https://doi.org/10.1002/jcc.20084) [Medline](#)
 48. H. McWilliam, W. Li, M. Uludag, S. Squizzato, Y. M. Park, N. Buso, A. P. Cowley, R. Lopez, Analysis Tool Web Services from the EMBL-EBI. *Nucleic Acids Res.* **41**, W597–W600 (2013). [doi:10.1093/nar/gkt376](https://doi.org/10.1093/nar/gkt376) [Medline](#)
 49. T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W. T. He, O. Limbo, C. Smith, G. Song, J. Woehl, L. Yang, R. K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, M. Parren, L. Peng, S. Ramirez, J. Ricketts, M. J. Ricciardi, S. A. Rawlings, N. C. Wu, M. Yuan, D. M. Smith, D. Nemazee, J. R. Teijaro, J. E. Voss, I. A. Wilson, R. Andrabi, B. Briney, E. Landais, D. Sok, J. G. Jardine, D. R. Burton, Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science* **369**, 956–963 (2020). [doi:10.1126/science.abc7520](https://doi.org/10.1126/science.abc7520) [Medline](#)
 50. L. M. Walker, S. K. Phogat, P.-Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T. Wrin, M. D. Simek, S. Fling, J. L. Mitcham, J. K. Lehrman, F. H. Priddy, O. A. Olsen, S. M. Frey, P. W. Hammond, S. Kaminsky, T. Zamb, M. Moyle, W. C. Koff, P. Poignard, D. R. Burton, Protocol G Principal Investigators, Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. *Science* **326**, 285–289 (2009). [doi:10.1126/science.1178746](https://doi.org/10.1126/science.1178746) [Medline](#)
 51. V. Tretter, F. Altmann, L. März, Peptide- N^4 -(N -acetyl- β -glucosaminyl)asparagine amidase F cannot release glycans with fucose attached $\alpha 1 \rightarrow 3$ to the asparagine-linked N -acetylglucosamine residue. *Eur. J. Biochem.* **199**, 647–652 (1991). [doi:10.1111/j.1432-1033.1991.tb16166.x](https://doi.org/10.1111/j.1432-1033.1991.tb16166.x) [Medline](#)
 52. E. Staudacher, V. Kubelka, L. März, Distinct N-glycan fucosylation potentials of three lepidopteran cell lines. *Eur. J. Biochem.* **207**, 987–993 (1992). [doi:10.1111/j.1432-1033.1992.tb17134.x](https://doi.org/10.1111/j.1432-1033.1992.tb17134.x) [Medline](#)

ACKNOWLEDGMENTS

We thank Bill Anderson, Hannah L. Turner and Charles A. Bowman for their help with electron microscopy, data acquisition and data processing. We thank Bill Webb and Linh Truc Hoang for their assistance with mass spectrometry and data processing. We thank Lauren Holden for her assistance with the manuscript.

Authors would also like to thank Ann M. Greene at Novavax, Inc. for editing the manuscript. **Funding:** This work was supported by grants from the National Institute of Allergy and Infectious Diseases Center for HIV/AIDS Vaccine Development UM1 AI144462 (J.C.P., A.B.W.), R01 AI113867 (J.C.P.), R01 AI132317 (D.N.), P01 AI110657 (A.B.W.), the Bill and Melinda Gates Foundation OPP1170236 (A.B.W.) and by Novavax, Inc. Molecular graphics and analyses performed with UCSF Chimera developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from National Institutes of Health R01-GM129325 and P41-GM103311, and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases. **Author contributions:** S.B and A.B.W conceived and designed the study. S.B, H.L.T, G.O and A.A performed cryo-EM data collection, data processing and model building. X.W, J.D, J.R.Y III and J.C.P performed site-specific glycan analysis and data interpretation. J.L.T, D.H and D.N performed mutagenesis and pseudovirus assays. S.B, G.O and A.B.W analyzed and interpreted data. S.B and A.B.W wrote the paper and all authors reviewed and edited the paper. J.H.T, A.D.P, N.P, M.J.M, G.G, and G.S contributed NVX-CoV2373 and Matrix-M adjuvant and provided advice for sample handling. J.H.T, A.D.P, N.P, M.J.M, G.G, and G.S also contributed to drafting of the manuscript. **Competing interests:** Authors J.H.T, A.D.P, N.P, M.J.M, G.G, and G.S are current employees of Novavax, Inc., a for-profit organization, and these authors own stock or hold stock options. These interests do not alter the authors' adherence to policies on sharing data and materials. Authors H.L.T. and A.B.W. are inventors on U.S. patent application no. 62/412,703 ("Prefusion Coronavirus Spike Proteins and Their Use"). All other authors have no competing interests to declare. **Data and materials availability:** The EM maps have been deposited at the Electron Microscopy Data Bank (EMDB) with accession codes EMD-22352 (SARS-CoV-2 3Q-2P-FL spike trimer with C3 symmetry), EMD-22353 (SARS-CoV-2 3Q-2P-FL spike trimer with C1 symmetry), EMD-22354 (SARS-CoV-2 3Q-2P-FL spike dimer-of-trimers with C2 symmetry), EMD-22355 (SARS-CoV-2 3Q-2P-FL spike trimer-of-trimers with C1 symmetry) and EMD-22356 (SARS-CoV-2 3Q-FL spike trimer with C3 symmetry). The atomic models have been deposited at the Protein Data Bank with PDB IDs 7JJ1 (SARS-CoV-2 3Q-2P-FL spike trimer with C3 symmetry) and 7JJJ (SARS-CoV-2 3Q-2P-FL spike dimer-of-trimers with C2 symmetry). The vaccine construct was provided to the Scripps Research Institute under a Material Transfer Agreement with Novavax. Requests for this material should be addressed to Gale Smith at Novavax. Other materials are available from Andrew Ward under a Material Transfer Agreement with the Scripps Research Institute. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <https://creativecommons.org/licenses/by/4.0/>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.

SUPPLEMENTARY MATERIALS

science.sciencemag.org/cgi/content/full/science.abe1502/DC1

Materials and Methods

Figs. S1 to S4

Table S1

References (32–52)

MDAR Reproducibility Checklist

3 August 2020; accepted 13 October 2020

Published online 20 October 2020

10.1126/science.abe1502

A.

B.

C.

D.

S1 subunit

S2 subunit

Fig. 2. Cryo-EM analysis of SARS-CoV-2 3Q-2P-FL spikes. (A) Representative electron micrograph and 2D class averages of 3Q-2P-FL spikes showing free trimers and complexes of trimers. (B) Side and top views of the B-factor-sharpened cryo-EM map of 3Q-2P-FL free trimers showing the spike in prefusion state, with the RBDs in closed conformation. The protomers are colored in blue, green and coral for clarity. (C) Side and top view of the atomic model of free trimer represented as a ribbon diagram fit into the map density. The protomers are colored in blue, green and coral and the map is shown as a transparent gray density. (D) Comparison of 3Q-2P-FL spike with published structures (PDB IDs 6VXX and 6VSB) on a subunit level. PDB 6VXX is shown in cyan, PDB 6VSB shown in blue and 3Q-2P-FL spike in coral.

Fig. 3. Structural features of the SARS-CoV-2 3Q-2P-FL spike trimer. (A) Interprotomeric salt-bridge interaction between D614 and K854 in 3Q-2P-FL spike trimer. (B) Comparison of the 615-635 loop between 3Q-2P-FL spike shown in coral and PDB 6X6P shown in blue. The residues that were built in 6X6P model but not in our model are shown in dark blue. Threonines at positions 618 and 632 flanking the gap in the 3Q-2P-FL trimer model are shown on both models to highlight their relative positions. (C) Linoleic acid (Dark blue) binding within a hydrophobic pocket of one RBD where the fatty acid head group reaches out to interact with the closed RBD of the adjacent protomer. The interacting residues are shown in pink. (D) Polysorbate 80 detergent (blue) binding within the NTD with potential hydrogen bonding with R190 and H207. The interacting residues are shown in orange. Adjacent protomers are shown in yellow and gray in (A), (C), and (D).

Fig. 4. Trimer-trimer interactions and glycan analysis. (A) Side and top views of the sharpened cryo-EM map of 3Q-2P-FL dimers of spike trimers. Individual spike trimers are shown in blue and coral along a two-fold axis of symmetry (dotted line). (B) Top view of the B-factor-sharpened cryo-EM map of trimer-of-trimers complex with individual trimers colored in blue, coral and green. (C) Ribbon representation of a protomer from one trimer (blue) interacting with the protomer from the adjacent trimer (coral) docked into the dimers-of-trimers density. (D) A close-up view of the interaction between the protomers of adjacent trimers. One protomer is shown as a ribbon diagram in blue while its binding partner is shown as surface in gray. Residues 621-PVAIHADQ-628 in the loop with potential interactions to the neighboring NTD are colored yellow and the residues in the NTD binding pocket are highlighted in coral. Residue D614 at the start of the loop is highlighted in dark blue. Glycosylation at residue 616 is not shown for clarity. (E) Changes occurring in the binding pocket in the bound state (gray) versus the free trimer (pink). Y145 and H146 switch positions to accommodate the loop better, also resulting in salt bridge formation between H146 and D627. It also results in stacking between W152 and H146. (F) Pseudoviruses expressing SARS-CoV-2 WT or mutant spikes were used to infect HeLa or HeLa-ACE2 cells for 42 to 48 hours. Infection was measured by luciferase intensity RLU (Relative Light Unit) in the lysed cells following infection. (G) Correlation between pseudovirus infection (RLU) and surface expression of SARS-CoV-2 spike variants in 293T cells measured by MFI (Mean Fluorescence Intensity). (H) Site-specific glycan analysis of 3Q-2P-FL spike protein expressed in SF9 insect cell line. Proportions shown for no occupancy, oligomannose and complex/paucimannose PNGS are the average and SEM of 3-32 unique peptides for each glycosite except for sites 17, 709 and 717 where only a single peptide was observed.